MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keae440

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome.

Caorsi Roberta, Bertoni Arinna, Matucci-Cerinic Caterina, Natoli Valentina, Palmeri Serena, Rosina Silvia, Penco Federica, Malattia Clara, Consolaro Alessandro, Viola Stefania, Papa Riccardo, Corcione Anna, Volpi Stefano, Ravelli Angelo, Gattorno Marco

СтатьяКлинический случайПеревод в очереди

Аннотация

INTRODUCTION

Systemic JIA (sJIA), a multifaceted autoinflammatory disorder, can be complicated by life-threatening conditions such as macrophage activation syndrome (MAS) and interstitial lung disease. The management of these conditions presents a therapeutic challenge, underscoring the need for innovative treatment approaches.

OBJECTIVES

To report the possible role of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in the treatment of multi-drug-resistant sJIA.

METHODS

We report two patients affected by sJIA with severe and refractory MAS and high serum IL-18 levels, responding to dual blockade of IL-1β and IL-18.

RESULTS

The first patient is a 20-year-old man, presenting a severe MAS complicated by thrombotic microangiopathy, following SARS-CoV-2 infection. He was treated with MAS825, with quick improvement. Eighteen months later, the patient is still undergoing biweekly treatment with MAS825, associated with MTX, ciclosporin and low-dose glucocorticoids, maintaining good control over the systemic features of the disease. The second patient, a 10-year-old girl, presented a severe MAS case, complicated by posterior reversible encephalopathy syndrome, following an otomastoiditis. The MAS was not fully controlled despite treatment with i.v. high-dose glucocorticoids, anakinra and ciclosporin. She began biweekly MAS825, which led to a prompt amelioration of MAS parameters. After 10 months, the patient continues to receive MAS825 and is in complete remission.

CONCLUSION

In light of the pivotal role of IL-1β and IL-18 in sJIA, MAS and interstitial lung disease, MAS825 might represent a possible valid and safe option in the treatment of drug-resistant sJIA, especially in the presence of high serum IL-18 levels.

Для цитирования: Caorsi Roberta, Bertoni Arinna, Matucci-Cerinic Caterina, Natoli Valentina, Palmeri Serena, Rosina Silvia, Penco Federica, Malattia Clara, Consolaro Alessandro, Viola Stefania, Papa Riccardo, Corcione Anna, Volpi Stefano, Ravelli Angelo, Gattorno Marco. Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keae440.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.